At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
lenalidomidedrug
Likely dose
lenalidomide 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating lenalidomide for Lymphoma. Completed, enrolled 33 participants across 3 sites.
Detailed Summary
RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2005
First PostedApr 2007
Primary CompletionApr 2010
Study CompletionMay 2013
TodayJul 2026
First PostedApr 27, 2007
Enrollment StartApr 19, 2005
Primary CompletionApr 5, 2010
Study CompletionMay 17, 2013
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 19.2 years ago
Interventions
lenalidomidedrug
10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.